Skip Navigation



Carcinogenesis Advance Access published online on April 25, 2006

Carcinogenesis, doi:10.1093/carcin/bgl048
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
27/10/2034    most recent
bgl048v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Huang, M.
Right arrow Articles by Wu, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, M.
Right arrow Articles by Wu, X.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Received January 1, 2006
Revised April 6, 2006
Accepted April 11, 2006

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions

Maosheng Huang 1, Margaret R. Spitz 1, Jian Gu 1, J. Jack Lee 2, Jie Lin 1, Scott M. Lippman 3, and Xifeng Wu 1 *

1 Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030
2 Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030
3 Department of Thoracic/Head and Neck Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

* To whom correspondence should be addressed.
Xifeng Wu, E-mail: xwu{at}mdanderson.org


   Abstract

Background: Deregulation of cell cycle plays an important role in tumorigenesis. Cyclin D1 gene (CCND1) is a key regulator of the G1 phase of the cell cycle. Methods: In this case control study of 115 oral premalignant lesion (OPL) patients and 230 controls, we genotyped the CCND1 single nucleotide polymorphism (SNP) at the exon 4 splice site (G870A) and determined the association of this SNP with the risk of developing OPLs. Results: We found significant associations between the heterozygous variant allele (GA), the homozygous variant allele (AA), and OPL risk, with adjusted odds ratios (ORs) of 1.91 (95% CI, 1.05-3.48) and 2.38 (95%CI, 1.16-4.87), respectively. The OR for individuals with at least one variant allele was 2.04 (95%CI, 1.15-3.60). When further stratified analyses were performed, the increased risk was more evident in younger individuals (OR=2.82, 95% CI, 1.32-6.02), in men (OR=2.97, 95%CI, 1.31-6.71), and in never smokers (OR=2.92, 95% CI, 1.09-7.82). Finally, we found joint effects between the variant alleles and smoking status. Using never smokers with the wild type (GG) genotypes as the reference group, the ORs for never smokers with the variant genotypes (G/A + A/A), smokers with the G/G genotype, and smokers with the G/A + A/A genotypes were 2.92 (1.09-7.82), 3.95 (1.36-11.5), and 7.01 (2.68-18.4), respectively. Conclusion: Our results suggest that the CCND1 G870A SNP may contribute to genetic susceptibility to OPLs and involve in oral cancer development.

Keywords: Oral premalignant lesions; Cyclin D1; SNP.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. L. Goode, B. L. Fridley, R. A. Vierkant, J. M. Cunningham, C. M. Phelan, S. Anderson, D. N. Rider, K. L. White, V. S. Pankratz, H. Song, et al.
Candidate Gene Analysis Using Imputed Genotypes: Cell Cycle Single-Nucleotide Polymorphisms and Ovarian Cancer Risk
Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 935 - 944.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
S. J. Freemantle, Y. Guo, and E. Dmitrovsky
Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs
Cancer Prevention Research, January 1, 2009; 2(1): 3 - 6.
[Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
V. Papadimitrakopoulou, J. G. Izzo, D. D. Liu, J. Myers, T. L. Ceron, J. Lewin, W. N. William Jr., A. Atwell, J. J. Lee, A. Gillenwater, et al.
Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients
Cancer Prevention Research, January 1, 2009; 2(1): 14 - 21.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J. Marsit, C. C. Black, M. R. Posner, and K. T. Kelsey
A Genotype-Phenotype Examination of Cyclin D1 on Risk and Outcome of Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., April 15, 2008; 14(8): 2371 - 2377.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.